Class / Patent application number | Description | Number of patent applications / Date published |
530328000 | 8 to 10 amino acid residues in defined sequence | 77 |
20080234467 | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis - The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage including a pharmacologically active peptide sequence (X) and a stabilising peptide sequence (Z) covalently bound to X. | 09-25-2008 |
20080249284 | GENE ENCODING LABYRINTHIN, A MARKER FOR CANCER - A cDNA molecule that encodes a protein designated Labyrinthin (Lab) is isolated and its nucleotide sequence is determined. The protein, or peptides derived from the protein, are markers useful to define novel classes of cancers. Diagnostic assays for these cancers use antibodies to Lab or nucleotide probes that hybridize with the lab gene or a fragment therefrom. Vaccines useful either to prevent recurrence of cancers in subjects who test positive for Lab (or lab) or to prevent initial occurrence of cancer, use proteins or peptides derived from Lab. Expression of Lab via immunogenic assays is used to monitor effects of cancer treatments. Antisense molecules against lab are used in treatments. Sense molecules of lab are used to restore lost lab function in diseased normal cells, for example, gland cells. | 10-09-2008 |
20080319163 | Method for Isolating and Purifying Immuno-Modulating Polypeptide from Cow Placenta - The present invention provides a method for isolating and purifying immuno-modulating polypeptide from cow placenta, which is characterized by using the steps of anion-exchange chromatography, gel exclusion chromatography and reverse-phase high performance liquid chromatography to isolate and purify immuno-modulating polypeptide from cow placenta, identifying its activity of stimulating lymphocyte proliferation in vitro by MTT method, then determining its molecular weight by MALDI-TOF-MS, its isoelectric point by CIEF and its amino acid sequence with analyzer for protein sequencing. Since the obtained immuno-modulating polypeptide by the method according to the present invention has more than 90% purity, its bioactivity can reach medicinal standards. | 12-25-2008 |
20080319164 | SYNTHESIS AND APPLICATION OF A FAMILY OF NEW MATERIALS RESULTING FROM THE CHEMICAL CROSS-LINKING BETWEEN GELATINE AND ORGANIC SALTS - The Scheme (I) illustrates the synthesis mechanism of the new materials. This invention involves the combination of gelatine with organic salts in the solid or liquid state. For that purpose, gelatines of several origins (animal, microbial, vegetal) can be used. | 12-25-2008 |
20090005535 | Solution-Phase Synthesis of Leuprolide and Its Intermediates - The invention relates to a process for producing the nonapeptide leuprolide and the intermediate N-protected oligopetides thereof, wherein at least one peptide bond of the compound is formed by reacting an activated carboxylic acid and an amine component in a continuous flow. | 01-01-2009 |
20090012262 | Forisomes, Method for Their Isolation, and Their Use as a Molecular Working Machine - A protein body derivable from Fabaceae has a reversible, anisotropic contractability such that the protein body becomes thicker perpendicular to a longitudinal axis of the protein body and shorter along the longitudinal axis of the protein body when increasing a calcium ion concentration in a medium surrounding the protein body past a threshold value of 30 nM. The protein body becomes thinner perpendicular to the longitudinal axis and longer along the longitudinal axis when decreasing the calcium ion concentration below the threshold value of 30 nM. Also, the protein body becomes thicker in the direction perpendicular to the longitudinal axis when increasing a pH value of a medium surrounding the protein body to a value above 9.5 without becoming shorter along the longitudinal axis. The protein body becomes thinner in the direction perpendicular to the longitudinal axis without becoming longer decreasing the pH value below 9.5. | 01-08-2009 |
20090023896 | COMPOUNDS WITH A SULPHONAMIDE GROUP AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS - This invention relates to compounds that as prodrugs and/or vehicles make it possible for an active ingredient to be taken up into erythrocytes and/or an active ingredient to bind to erythrocytes, whereby the uptake of the compounds into erythrocytes and/or the binding of the compounds to erythrocytes is made possible by a group —SO | 01-22-2009 |
20090030181 | Peptides for Inhibiting MDM2 Function - Disclosed are peptides for inhibiting mdm2 (mouse double minute 2) and a pharmaceutical composition comprising the same. | 01-29-2009 |
20090093615 | METASTIN DERIVATIVES AND USE THEREOF - The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotrophic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). By substituting the constituent amino acids of metastin with specific amino acids in the metastin derivative of the present invention, blood stability, solubility, etc. are more improved, gelation tendency is reduced, pharmacokinetics are also improved, and an excellent cancer metastasis suppressing activity or a cancer growth suppressing activity is exhibited. Furthermore, the metastin derivative of the present invention has the effects of suppressing gonadotropic hormone secretion, suppressing sex hormone secretion, etc. | 04-09-2009 |
20090099334 | METASTIN DERIVATIVES AND USE THEREOF - The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotrophic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). By substituting the constituent amino acids of metastin with specific amino acids in the metastin derivative of the present invention, blood stability, solubility, etc. are more improved, gelation tendency is reduced, pharmacokinetics are also improved, and an excellent cancer metastasis suppressing activity or a cancer growth suppressing activity is exhibited. Furthermore, the metastin derivative of the present invention has the effects of suppressing gonadotropic hormone secretion, suppressing sex hormone secretion, etc. | 04-16-2009 |
20090099335 | Polyomavirus Diagnostic Reagents - The present invention relates to HLA-A*02-restricted cellular epitopes within the VP1 polypeptide of human polyomaviruses, which are useful as diagnostic reagents for virus infection. Preferred peptides correspond to amino acids residues 107-116, 108-116 and 44-52 of BKV VP1, and are processed in vivo in natural infection with BKV. Effector T cell populations stimulated by the peptides represent functional CTLs as assessed by cytotoxicity and cytokine production, and are reactive against cells presenting both the BKV peptides above and the JC virus homolog sequences. | 04-16-2009 |
20090105448 | METHODS FOR THE SPECIFIC PREPARATION OF LYSOBACTIN FRAGMENTS - The invention relates to methods for the targeted production of lysobactin derivatives by combined chemical and enzymatic modifications. In particular, the invention relates to method for preparing lysobactin fragment 4-11 by chemical reduction and cleavage of the resultant product by chymotrypsin. | 04-23-2009 |
20090253896 | SELECTIVE SUBSTRATES FOR MATRIX METALLOPROTEINASES - The invention provides isolated MMP-2, MMP-9 and MT1-MMP selective substrate polypeptides or functional peptidomimetics. The selective substrate polypeptides contain the following sequences: MMP-2 selective substrate polypeptides contain SEQ ID NOS:1-27, MMP-9 selective substrate polypeptides contain SEQ ID NOS:28-35, and MT1-MMP selective substrate polypeptide contain SEQ ID NOS:36-40. In addition, the invention provides a method of preferentially directing a moiety to a site of MMP-2 activity by administering to a subject an effective amount of an isolated MMP-2 selective substrate polypeptide containing SEQ ID NOS:45-47 linked to a moiety. Also provided is a method of preferentially directing a moiety to a site of MMP-9 activity by administering to a subject an effective amount of an isolated MMP-9 selective substrate polypeptide containing SEQ ID NO:44 linked to a moiety, and preferentially directing a moiety to a site of MT1-MMP activity by administering to a subject an effective amount of an isolated MT1-MMP selective substrate polypeptide containing SEQ ID NOS:36-40 linked to a moiety. | 10-08-2009 |
20090259020 | HIGHLY FLUORINATED BETA-AMINO ACIDS AND METHODS OF MAKING AND USING SAME - Disclosed are compounds having the structure: | 10-15-2009 |
20100076175 | MOLECULES THAT SELECTIVELY HOME TO VASCULATURE OF PREMALIGNANT OR MALIGNANT LESIONS OF THE PANCREAS AND OTHER ORGANS - The invention provides a conjugate that includes a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to vasculature of premalignant pancreas. The peptide or peptidomimetic contains at least 5 contiguous amino acids of an amino acid sequence selected from CRSRKG (SEQ ID NO:9) and CEYQLDVE (SEQ ID NO:34), or a conservative variant or peptidomimetic thereof. The invention additionally provides a conjugate containing a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to pancreatic tumor cells and pancreatic tumor vasculature, the peptide or peptidomimetic comprising at least 5 contiguous amino acids of an amino acid sequence selected from CKAAKNK (SEQ ID NO:15), CKGAKAR (SEQ ID NO:19), and VGVGEWSV (SEQ ID NO:35), or a conservative variant or peptidomimetic thereof. | 03-25-2010 |
20100087621 | IMMUNE REACTIVITY TO HER-2/NEU PROTEIN FOR DIAGNOSIS AND TREATMENT OF MALIGNANCIES IN WHICH THE HER-2/NEU ONCOGENE IS ASSOCIATED - Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e.g., by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies. | 04-08-2010 |
20100093975 | IMIDAZOLIUM-TYPE IONIC OLIGOMERS - The present disclosure relates to structurally defined imidazolium-type ionic oligomers of the formula: | 04-15-2010 |
20100130722 | POLYMERIC CARRIER FOR DELIVERY OF SMALL INTERFERING RNA - A carrier for delivering small interfering RNA (siRNA) into cells includes a cholesterol residue covalently bonded to oligoarginine. Mixing the siRNA with the carrier produces a complex-containing composition. Contacting a cell with the complex-containing composition results in delivery of the siRNA into the cell. Delivery of an siRNA targeted to vascular endothelial growth factor is a treatment for cancer. Methods of making the carrier and complex are also disclosed. | 05-27-2010 |
20100152421 | SPARC-DERIVED TUMOR REJECTION ANTIGENIC PEPTIDES AND MEDICAMENTS COMPRISING THE SAME - It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following:
| 06-17-2010 |
20100204448 | METHOD AND CARRIER COMPLEXES FOR DELIVERING MOLECULES TO CELLS - The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide. | 08-12-2010 |
20100216973 | METHODS FOR THE SPECIFIC PREPARATION OF LYSOBACTIN FRAGMENTS - The invention relates to methods for the targeted production of lysobactin derivatives by combined chemical and enzymatic modifications. In particular, the invention relates to method for preparing lysobactin fragment 4-11 by chemical reduction and cleavage of the resultant product by chymotrypsin. | 08-26-2010 |
20100222548 | METHOD FOR PRODUCING CONDENSATION PRODUCTS FROM N-SUBSTITUTED GLYCINE DERIVATIVES(PEPTOIDS) BY SEQUENTIAL UGI-MULTICOMPONENT REACTIONS - The present invention relates to a process for the preparation of condensates (peptoids) from N-substituted glycine derivatives via sequential Ugi multicomponent reactions, to compounds prepared thus, and to their use as pharmaceutically useful products, in particular as antibiotics, antiinfectives and for all pharmacological applications in relation to the necessity of cell wall permeability or cell wall localization. | 09-02-2010 |
20100222549 | DECHALCOGENATIVE METHODS FOR THE PREPARATION OF ALLYLIC SULFIDES - A dechalcogenative method for the preparation of an allylic sulfide comprises contacting an activated chalcogenide of Formula (I) with a thiol of Formula (II) for a period of time sufficient to form an intermediate of Formula (III), and supplying sufficient activation energy to the intermediate of Formula (III), in a suitable solvent, preferably in the absence of a phosphine or other thiophile, to induce a [2,3]-sigmatropic rearrangement therein to form an allylic sulfide of Formula (IV), with concomitant loss of chalcogen Z, as set forth in the following reaction scheme, wherein X is an activating group selected from the group consisting of CN, S-pyridyl, S-heteroaryl, SO2-aryl, and SO3Y; Y is an alkali metal ion; Z is Se or S; R1, R2, R3, R4, and R5 are each independently H or a hydrocarbon moiety; and R is an organic moiety. | 09-02-2010 |
20100280221 | Peptide production and purification process - Processes for the synthesis and purification of a Gly-Gly-Val-Leu-Val-Gln-Pro-Gly octapeptide (SEQ ID NO 1). | 11-04-2010 |
20100311946 | Solid Phase Peptide for the Production of Goserelin - The present invention provides a process for the production of goserelin. In particular, the process of the invention allows the use of side chain protecting groups during synthesis of the peptide, and the addition of the azaglycine moiety of the peptide. | 12-09-2010 |
20100317830 | BACE455, AN ALTERNATIVE SPLICE VARIANT OF THE HUMAN BETA-SECRETASE - The present invention relates generally to the fields of genetics, biochemistry, medicinal chemistry and medicine. The present invention more particularly discloses the identification of a human gene variant involved in neuropathological conditions, and methods for the diagnosis, prevention and treatment of such diseases and related disorders, as well as for the screening of therapeutically active drugs. The present invention relates to catalytically active beta-secretase (Memapsin2, BACE) variants, and nucleic acids encoding them. The invention is useful in the identification of agents that inhibit the activity of a particular BACE isoform and thus agents and therapies affecting the genesis, development or progression of neuropathological conditions, including Alzheimer's disease and dementia. | 12-16-2010 |
20100324264 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS - The present invention provides novel synthesis's for obtaining a protecting group aminoxy PEG-6 linker from cost effective, and readily available starting materials and chemicals or modified polyethylene glycols. More specifically, a novel synthesis of obtaining a modified Boc-protected aminoxy PEG-6 linker was achieved so that said linker may be attached to a vector such as a peptide based fragment. | 12-23-2010 |
20100331520 | METASTIN DERIVATIVES AND USE THEREOF - The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotrophic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). By substituting the constituent amino acids of metastin with specific amino acids in the metastin derivative of the present invention, blood stability, solubility, etc. are more improved, gelation tendency is reduced, pharmacokinetics are also improved, and an excellent cancer metastasis suppressing activity or a cancer growth suppressing activity is exhibited. Furthermore, the metastin derivative of the present invention has the effects of suppressing gonadotropic hormone secretion, suppressing sex hormone secretion, etc. | 12-30-2010 |
20110015370 | EX-VIVO PRIMING FOR GENERATING CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR NON-TUMOR ANTIGENS TO TREAT AUTOIMMUNE AND ALLERGIC DISEASE - Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo. In contrast, CTL induced by antigenic peptides derived from IgE specifically inhibit IgE responses, and adoptive transfer of CD40L-specific CTL to NOD mice at early age delay the development of diabetes in NOD mice. In vitro generated CTL specific for non-tumor self-antigens expressed on activated CD4 T cells regulate immune responses in vivo. | 01-20-2011 |
20110021747 | EX-VIVO PRIMING FOR GENERATING CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR NON-TUMOR ANTIGENS TO TREAT AUTOIMMUNE AND ALLERGIC DISEASE - Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo. In contrast, CTL induced by antigenic peptides derived from IgE specifically inhibit IgE responses, and adoptive transfer of CD40L-specific CTL to NOD mice at early age delay the development of diabetes in NOD mice. In vitro generated CTL specific for non-tumor self-antigens expressed on activated CD4 T cells regulate immune responses in vivo. | 01-27-2011 |
20110213123 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES - The present invention provides modified cycloalkyne compounds; and method of use of such compounds in modifying biomolecules. The present invention features a cycloaddition reaction that can be carried out under physiological conditions. In general, the invention involves reacting a modified cycloalkyne with an azide moiety on a target biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provide for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids). | 09-01-2011 |
20110263819 | SIMPLIFIED ONE-POT SYNTHESIS OF [18F]SFB FOR RADIOLABELING - A non-aqueous single pot synthesis of [ | 10-27-2011 |
20110269938 | AMYLOID-BETA PEPTIDE CRYSTAL STRUCTURE - The invention relates provides a novel crystal structure of the fibrillogenic part of amyloid β-peptide (Aβ). More specifically the crystal structure is Aβ-IgNAR and, accordingly the present invention also relates to selecting and/or designing compounds that modulate amyloid β-peptide (Aβ) activity using techniques such as in silico screening and crystal soaking experiments. The invention further relates to compounds and methods for inhibiting interaction between amyloid β-peptide (Aβ) monomers, more particularly, inhibiting or disrupting amyloid β-peptide (Aβ) oligomer formation and toxic activity. | 11-03-2011 |
20120041172 | METHOD FOR THE MANUFACTURE OF DEGARELIX - In a step-wise synthesis of degarelix comprising 0.3% by weight or less of 4-([2(5-hydantoyl)]acetylamino)-phenylalanine analog on (solid support)-NH | 02-16-2012 |
20120123090 | NOVEL TUMOR ANTIGEN PROTEIN SART-3 AND TUMOR ANTIGEN PEPTIDES THEREOF - A novel tumor antigen protein and gene therefor, tumor antigen peptides derived from said tumor antigen protein or derivatives thereof as well as medicaments, prophylactics, or diagnostics for tumors using such tumor substances in vitro or in vitro are provided. | 05-17-2012 |
20120142894 | Identification, Optimization and Use of Shared HLA-B*0702 Epitopes for Immunotherapy - The present invention provides novel methods and materials for efficiently treating patients having an HLA-B*0702 phenotype, based on peptides representing shared epitopes of tumour antigens. In particular, the invention relates to a method for identifying a HLA-B*0702-restricted peptide which can trigger a cytotoxic response against several antigens from one single multigenic family, and to several such epitopes. | 06-07-2012 |
20120178902 | METHOD FOR OBTAINING 68GA - The present invention relates to a method of obtaining | 07-12-2012 |
20120178903 | Methods and Compositions Related to Adenoassociated Virus-Phage Particles - Embodiments of the invention are generally directed to compositions and methods of delivering one or more transgene to a target cell, such as a tumor cell, in a site-specific manner to achieve enhanced expression and to constructs and compositions useful in such applications. In certain aspects, expression from a therapeutic nucleic acid may be assessed prior to administration of a treatment or diagnostic procedure to or on a subject. | 07-12-2012 |
20120259092 | NPY ANTAGONISTS - Peptidic NPY antagonists selective for Y | 10-11-2012 |
20120289682 | Tyrosine Bioconjugation through Aqueous Ene-Like Reactions - A new and versatile class of cyclic diazodicarboxamides that reacts efficiently and selectively with phenols and the phenolic side chain of tyrosine through an Ene-like reaction is reported. This mild aqueous tyrosine ligation reaction works over a broad pH range and expands the repertoire of aqueous chemistries available for small molecule, peptide, and protein modification. The tyrosine ligation reactions are shown to be compatible with the labeling of native enzymes and antibodies in buffered aqueous solution. This reaction provides a novel synthetic approach to bispecific antibodies. This reaction will find broad utility in peptide and protein chemistry and in the chemistry of phenol-containing compounds. | 11-15-2012 |
20120302729 | ANTICANCER ANTI-MORTALIN PEPTIDE ANTIBODY - The present invention provides anti-mortalin peptide antibodies having stronger anticancer effects than known anti-mortalin antibodies, hybridomas producing such antibodies, and anticancer agents using such antibodies. Specifically, a hybridoma C-26 strain (FERM P-21875) and a hybridoma C-69 strain (FERM P-21876) producing anti-mortalin monoclonal antibodies having the function of being internalized by cancer cells and specificity to mortalin antigens, and having the good function of suppressing the cancer cell proliferation in vivo were obtained from hybridoma clones obtained using as an immunogen cocktail of the 2 types of peptide containing “LFGRAP” and “KAMQDAEVSKSDIGEVI” epitopes for an anti-mortalin antibody having the function of being internalized by cancer cells. Thus, anticancer agents containing the monoclonal antibodies as active ingredients could also be provided. Moreover, the epitope sequences recognized by these monoclonal antibodies were confirmed to be “EVILVG” and “DLFGR.” | 11-29-2012 |
20120316318 | POLYPEPTIDE SPECIFICALLY BINDING TO VASCULAR ENDOTHELIAL GROWTH FACTOR, FUSION PROTEIN INCLUDING POLYPEPTIDE, AND METHODS THEREFOR - A polypeptide inhibiting binding between a vascular endothelial growth factor and a vascular endothelial growth factor receptor, a fusion protein including the same, and a method of preparing the fusion protein are disclosed. | 12-13-2012 |
20130060004 | Novel Process For The Preparation Of Leuprolide And Its Pharmaceutically Acceptable Salts Thereof - The present invention relates to a novel process for the preparation of Leuprolide or its pharmaceutically acceptable salts thereof by solid and solution phase peptide synthesis (Hybrid approach). The present invention also relates to a process for the preparation of Leuprolide or its pharmaceutically acceptable salts thereof by synthesizing the peptide fragments by solid phase (7 and 5 amino acids fragment) and solution phase (2 and 4 amino acids fragment) respectively. The final solution phase condensation of these peptide fragments (7+2 and 5+4) led to a nonapeptide Leuprolide in the protected form. The present invention further relates to novel peptide fragements—Pyr-His(Trt)-Trp(Boc)-Ser(tBu)-Tyr(tBu)-DLeu-Leu-OH (Fragment-11); H-Arg(Pbf)-Pro-NHEt (Fragment-I11); Pyr-His(Trt)-Trp(Boc)-Ser(tBu)-Tyr(tBu)-DLeu-Leu-Arg(Pbf)-Pro-NHEt (Protected Leuprolide) (Fragment-IV); Pyr-His(Trt)-Trp(Boc)-Ser(tBu)-Tyr(tBu)-OH (Fragment-V); H-DLeu-Leu-Arg(Pbf)-Pro-NHEt (Fragment-VI) and process for the preparation thereof. | 03-07-2013 |
20130137851 | TARGETED DELIVERY OF ANTIMICROBIAL AGENTS - A cationic antimicrobial peptide (CAMP) conjugate is disclosed. The CAMP conjugate may be made by identifying a suitable carrier peptide; identifying a suitable antimicrobial agent; creating a conjugate by conjugating the peptide with the antimicrobial agent; and evaluating and refining the conjugate. The peptide may be short peptide based on the sequence of a CAMP, such as human β-defensin-3. The peptide can be directly connected to the antimicrobial agent or through a linker segment. The antimicrobial agent may be connected to the peptide or the linker segment through stable or cleavable bonding. The peptide may carry and facilitate the delivery of the conjugated antimicrobial agent to a microbe. | 05-30-2013 |
20130281661 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES - The present invention relates to a liquid (or solution)-phase manufacturing process for preparing the decapeptide Degarelix, its protected precursor, and other useful intermediates. The invention further relates to polypeptides useful in the solution-phase manufacturing process and to the purification of Degarelix itself. Degarelix can be obtained by subjecting a Degarelix precursor according to formula (II): (P | 10-24-2013 |
20130281662 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES - The present invention relates to a liquid (or solution)-phase manufacturing process for preparing the decapeptide Degareiix, its amino-protected precursor, and other useful intermediates. The invention further relates to polypeptides useful in the solution-phase manufacturing process and to the purification of Degareiix itself. The manufacturing process comprises the step of cleaving the ε-amino protecting group Pε from a Degareiix precursor according to formula {P | 10-24-2013 |
20130289238 | PAR4 AGONIST PEPTIDES - The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays. | 10-31-2013 |
20130289239 | METHOD FOR CROSS-LINKING PEPTIDES - The present invention relates to a method for cross-linking peptides using an activated furan-moiety. In particular, the present invention provides a method for cross-linking peptides comprising the steps of: a) providing a composition comprising furan-peptides, said furan-peptides comprising at least one amino acid comprising a furan-moiety; b) contacting said composition comprising furan-peptides with second peptides, thereby obtaining a mixture comprising furan-peptides and second peptides; c) adding an activation signal to said mixture of step b), thereby activating said furan-peptides to activated furan-peptides, and d) reacting said activated furan-peptides with said second peptides, thereby cross-linking said activated furan-peptides with said second peptides. | 10-31-2013 |
20140005359 | BRANCHED CHAIN-CONTAINING AROMATIC COMPOUND | 01-02-2014 |
20140031523 | Selective Poly-N-Substituted Glycine Antibiotics - Antimicrobial peptoid compounds and related compositions as can be used against bacteria effectively and selectively. | 01-30-2014 |
20140039155 | AMYLOID-BETA PEPTIDE CRYSTAL STRUCTURE - The invention relates provides a novel crystal structure of the fibrillogenic part of amyloid β-peptide (Aβ). More specifically the crystal structure is Aβ-IgNAR and, accordingly the present invention also relates to selecting and/or designing compounds that modulate amyloid β-peptide (Aβ) activity using techniques such as in silico screening and crystal soaking experiments. The invention further relates to compounds and methods for inhibiting interaction between amyloid β-peptide (Aβ) monomers, more particularly, inhibiting or disrupting amyloid β-peptide (Aβ) oligomer formation and toxic activity. | 02-06-2014 |
20140080998 | ACID-CLEAVABLE LINKERS EXHIBITING ALTERED RATES OF ACID HYDROLYSIS - An acid-cleavable peptide linker comprising aspartic acid and proline residues is disclosed. The acid-cleavable peptide linker provides an altered sensitivity to acid-hydrolytic release of peptides of interest from fusion peptides of the formula PEP1-L-PEP2. The inventive linker, L, is described in various embodiments, each of which provides substantially more rapid acid-release of peptides of interest than does a single aspartic acid-proline pair. In an additional aspect, a method of increasing the stability of an acid cleavable linkage to acid hydrolysis is also provided. | 03-20-2014 |
20140088290 | Novel Melanoma Antigen Peptide and Uses Thereof - The present invention relates to novel melanoma antigen peptides and specific T lymphocytes directed to said peptides and the use thereof for treating melanoma. | 03-27-2014 |
20140094586 | HLA-BINDING PEPTIDE, AND DNA FRAGMENT AND RECOMBINANT VECTOR CODING FOR SAID HLA-BINDING PEPTIDE - An HLA-binding peptide binding to a HLA-A type molecule, the HLA-binding peptide includes at least one type of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 80, and consists of not less than 8 and not more than 11 amino acid residues. All of these amino acid sequences herein mentioned are the predicted amino acid sequences binding to a human HLA-A type molecule with the prediction program using the certain active learnig method. | 04-03-2014 |
20140114052 | Palladium Catalyzed Reactions Executed on Solid-Phase Peptide Synthesis Supports for the Production of Self-Assembling Peptides Embedded with Complex Organic Electronic Subunits - Methods to synthesize self-assembling peptides embedded with complex organic electronic subunits are provided. | 04-24-2014 |
20140179901 | Peptide Conjugates and Fluorescence Detection Methods for Intracellular Caspase Assay - Polypeptides labelled with a donor and acceptor pair of dyes selected from a dibenzorhodamine dye and a diamino-benzophenoxazine dye are peptide conjugates which are useful for intracellular and bead-based assays with fluorescence detection. Peptide conjugates with a caspase-recognition site undergo cleavage into peptide fragments which may be detected, located, and quantitated by the changes in fluorescence. Intracellular cleavage of peptide conjugates is correlated with apoptosis. | 06-26-2014 |
20140187746 | PRECIPATABLE PEPTIDES - The invention is directed to a Ca2+ precipatable polypeptide tags and cassettes useful for purification of molecules from heterogeneous samples. The invention also relates to methods for bioseparation of molecules comprising Ca2+ precipatable tags and cassettes. | 07-03-2014 |
20140316107 | CYCLIN BASED INHIBITORS OF CDK2 AND CDK4 - Structural and functional analysis of peptide inhibitor binding to the cyclin D1 groove has been investigated and used to design peptides that provide the basis for structure-activity relationships, have improved binding and have potential for development as chemical biology probes, as potential diagnostics and as therapeutics in the treatment of proliferative diseases including cancer and inflammation. | 10-23-2014 |
20140336358 | METHODS AND COMPOSITIONS FOR TUMOR VACCINATION AND THERAPY - The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I complex of a target cell or antigen presenting cell. This external cellular presentation of these peptides promotes a specific cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells expressing these proteins, thereby, inducing immunological reactivity. | 11-13-2014 |
20140336359 | SYNTHETIC PEPTIDES FOR TREATMENT OF BACTERIAL INFECTIONS - Disclosed are peptides and methods for the treatment of bacterial infections and associated inflammation. Effective doses and treatment protocols are disclosed. | 11-13-2014 |
20140378654 | MUTATED ANTHRAX TOXIN PROTECTIVE ANTIGEN PROTEINS THAT SPECIFICALLY TARGET CELLS CONTAINING HIGH AMOUNTS OF CELL-SURFACE METALLOPROTEINASES OR PLASMINOGEN ACTIVATOR RECEPTORS - The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by administering a compound and a mutant protective antigen protein comprising a matrix metalloproteinase or a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the mutant protective antigen is cleaved by a matrix metalloproteinase or a plasminogen activator overexpressed by the cell, thereby translocating into the cell a compound comprising a lethal factor polypeptide comprising a protective antigen binding site. | 12-25-2014 |
20140378655 | STABILIZED FORMULATIONS OF PEPTIDES AND PROTEINS - Stabilization of water-containing solutions or lyophilizates of proteins and peptide against non-enzymatic deamidation degradation reactions at asparaginyl or glutaminyhl residues is achieved using organic anions, such as saccharin, benzenesulfonic acid, gentisic acide or N-acetyltryptophan which have a pKa within the range of 0.5 to 3.5 | 12-25-2014 |
20150057432 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules - The present application discloses compositions and methods of synthesis and use of | 02-26-2015 |
20150112043 | SMALL PEPTIDE SPECIFIC FOR LUNG CANCER AND APPLICATION THEREOF - A peptide including 8 animo acids having a sequence of cNGEGQQc, where c represents d-cysteine (Cys), N represents L-Asparagine (Asn), G represents L-Glycine (Gly), E represents L-Glutamic acid (Glu), and Q represents L-Glutamine (Gln). | 04-23-2015 |
20150112044 | Palladium Catalyzed Reactions Executed on Solid-Phase Peptide Synthesis Supports for the Production of Self-Assembling Peptides Embedded with Complex Organic Electronic Subunits - Methods to synthesize self-assembling peptides embedded with complex organic electronic subunits are provided. | 04-23-2015 |
20150299254 | NOVEL POLYMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME - Novel methods to prepare novel polymers are disclosed. Oxazolidinyl compounds according to formula IV: | 10-22-2015 |
20150315555 | Fragment Ligated Inhibitors Selective for the Polo Box Domain of PLK1 - Methods for developing non-peptidic inhibitors that target the polo-box domain of PLK1 proteins are described. Methods include developing structure activity relationships for peptidic inhibitors followed by development of non-peptide fragment alternatives for portions of the peptide inhibitors. The non-peptide fragment can provide similar structure activity relationship as the replaced peptide. Fragment alternatives to key binding determinants are identified in an iterative computational and synthetic process facilitated through understanding of the peptide structure-activity relationships. The approach is informed by peptide structure-activity data obtained through synthesis and testing of truncated and mutated analogs of known PBD binding motifs. | 11-05-2015 |
20150320761 | NEURONAL PAIN PATHWAY - The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk. | 11-12-2015 |
20150329593 | Synthesis of Beta-Arrestin Effectors - Embodiments disclosed herein provide compounds and methods for preparing Beta-Arrestin Effectors. | 11-19-2015 |
20150353487 | PROCESS FOR THE PREPARATION OF ASYMMETRICAL BIS(THIOSEMICARBAZONES) - The present invention relates to a method of making asymmetrical bis(thiosemicarbazones), compounds useful as synthetic intermediates in the method, new bis(thiosemicarbazones) that can be readily accessed by use of the method and methods of treatment and imaging utilising some of the new bis(thiosemicarbazones). | 12-10-2015 |
20150360146 | Purification of Organic Compounds Using Surrogate Stationary Phases on Reversed Phase Columns - There are only two ways to increase the amount of sample that can be purified by preparative reversed phase high performance liquid chromatography (Prep-RP-HPLC) in a single run: (1) The traditional approach is to use a bigger column (greater amount of stationary phase); and (2) Use displacement chromatography which uses the stationary phase more effectively. This invention describes a unique Prep-RP-HPLC technique that uses a C-18/C-8 derivatized silica coated with a hydrophobic quaternary ammonium salt or quaternary phosphonium salt to result in 7 to 12 fold increase in sample loading (of the crude mixture of organic compounds including synthetic crude peptides) in contrast to the conventional Prep-RP-HPLC technique. This increase in sample loading capacity and output is due to the additional surrogate stationary phase characteristic of the C-18/C8 bound quaternary salt. The quaternary surfactant is bound to the C-18/C-8 chains and silanols of the stationary phase. | 12-17-2015 |
20150361116 | NOVEL WATER-SOLUBLE COMPLEXING AGENTS AND CORRESPONDING LANTHANIDE COMPLEXES - The invention relates to complexing agents of formula (I): | 12-17-2015 |
20160016989 | Synthetic Polymers Containing Amino Acid Side Chains - A synthetic polymeric molecule containing multiple subunits in which one or more of the subunits contains an amino acid side chain linked to a phosphate or modified phosphate group and is attached to an adjacent subunit by a phosphodiester or modified phosphodiester bond. | 01-21-2016 |
20160024177 | Novel Epitope for Switching to TH1 Cell and Use Thereof - The present invention relates to a novel epitope that converts T cell to type 1 helper T (T | 01-28-2016 |
20160060295 | BIOLOGICALLY ACTIVE PEPTIDES - A peptide or peptide derivative comprising:
| 03-03-2016 |
20160145301 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES - The present invention relates to a liquid (or solution)-phase manufacturing process for preparing the decapeptide Degarelix, its protected precursor, and other useful intermediates. The invention further relates to polypeptides useful in the solution-phase manufacturing process and to the purification of Degarelix itself. Degarelix can be obtained by subjecting a Degarelix precursor according to formula II: (P | 05-26-2016 |
20160168197 | METHOD FOR CANCER IMMUNOTHERAPY | 06-16-2016 |